Treatment of mantle cell lymphoma: Current approach and future directions CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY Brody, J., Advani, R. 2006; 58 (3): 257-265

Abstract

Although mantle cell lymphoma has been described as "moderately aggressive" it has become clear that it carries a worse long-term prognosis than other subtypes of non-Hodgkin's lymphoma. In recent years, this has prompted numerous clinical trials of novel and more aggressive therapies in hopes of impacting these poor outcomes. These include more intensive combination chemotherapy regimens, monoclonal antibody therapy in conjunction with other treatments or conjugated to radioactive isotopes, high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation, and newer targeted therapies based on increasing understanding of the molecular pathways of this malignancy.

View details for DOI 10.1016/j.critrevonc.2005.10.001

View details for Web of Science ID 000238633200007

View details for PubMedID 16751087